
Krebs Biochemicals & Industries Ltd is Rated Strong Sell
2026-09-16 10:10:36Krebs Biochemicals & Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 February 2025. However, the analysis and financial metrics discussed below reflect the company’s current position as of 16 September 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trend, and technical outlook.
Read full news article
Krebs Biochemicals & Industries Ltd is Rated Strong Sell
2026-09-02 10:10:26Krebs Biochemicals & Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 February 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed here represent the company's current position as of 02 September 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trend, and technical outlook.
Read full news article
Krebs Biochemicals & Industries Ltd is Rated Strong Sell
2026-08-21 10:10:24Krebs Biochemicals & Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 February 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 21 August 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Krebs Biochemicals & Industries Ltd is Rated Strong Sell
2026-08-10 10:10:22Krebs Biochemicals & Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 February 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed here represent the stock's current position as of 10 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Krebs Biochemicals & Industries Ltd Reports Flat Quarterly Performance Amid Margin Improvements
2026-08-07 08:00:05Krebs Biochemicals & Industries Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended June 2026, signalling a pause in its recent downward trend. Despite some operational improvements, the company continues to face liquidity challenges and weak debtor management, which weigh on its overall financial health.
Read full news article
Krebs Biochemicals & Industries Ltd is Rated Strong Sell
2026-07-30 10:10:29Krebs Biochemicals & Industries Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Feb 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 30 July 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Krebs Biochemicals & Industries Ltd is Rated Strong Sell
2026-07-19 10:10:15Krebs Biochemicals & Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 Feb 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 19 July 2026, providing investors with an up-to-date view of its fundamentals, returns, and overall outlook.
Read full news article
Krebs Biochemicals & Industries Ltd Locks at Upper Circuit With 9.99% Gain — Buyers Queue, Sellers Absent
2026-07-09 12:00:06At Rs 59.43, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Krebs Biochemicals & Industries Ltd locked at its upper circuit of 9.99% on 9 Jul 2026, with buyers queuing and no sellers willing to part with shares.
Read full news article
Krebs Biochemicals & Industries Ltd Locks at Lower Circuit With 6.51% Loss — Sellers Queue, No Buyers in Sight
2026-07-08 12:00:07At Rs 54.39, sellers were still queuing — but there were no buyers willing to take the other side. Krebs Biochemicals & Industries Ltd locked at its lower circuit of 6.51% on 7 Jul 2026, with unfilled sell orders and a frozen price, reflecting a pronounced imbalance in supply and demand.
Read full news articleAnnouncement under Regulation 30 (LODR)-Newspaper Publication
07-Sep-2026 | Source : BSEThe Company has enclosed herewith copy of Newspaper Advertiesment of the Notice issued to shareholders wrt 34th AGM.
Reg. 34 (1) Annual Report.
04-Sep-2026 | Source : BSEWe are enclosing herewith copy of Annual Report for the financial year ended 31st March 2026.
Notice Of 34Th Annual General Meeting Of The Company
04-Sep-2026 | Source : BSEThe Company has enclosed herewith Notice of 34th AGM along with Annual Report FY 2025-26.
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
Krebs Biochemicals & Industries Ltd has announced 21:100 rights issue, ex-date: 31 Jan 19






